STGD1 clinical trials at UCSF
1 research study open to eligible people
Stargardt disease affects the retina and can cause progressive vision loss. UCSF is exploring the safety and effectiveness of tinlarebant in treating this condition. Researchers are seeing if patients can handle the treatment and if it improves their eyesight.
Showing trials for
Tinlarebant in Subjects With Stargardt Disease
open to eligible people ages 12-20
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
San Francisco, California and other locations
Last updated: